Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $1.98B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.41M
Average 1.23M
IMNM Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Immunome, Inc.NASDAQ: IMNM
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income growth accelerates
Q3 FY2026 net income of $85.78M (cash outflow) rose 49.3% year over year, ahead of the +26.9% change in trailing-twelve-month net income. Sequentially, it rose 17.3% from the prior quarter. Over 3 fiscal years it compounded at +79.2% a year.
Context
- Net income amounted to 3060.0% of revenue in FY2025, down 180.4 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$221.64M (+4.4%) for the fiscal year ending Dec 2026, a step up from the -27.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$85.78M+17.3% QoQ
- Last fiscal yearDec 2025
- -$212.39M-27.5% YoY
- LTMSep 2026
- -$282.65M+26.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +49.3% | +17.7% | -31.6 pp |
| 1 year | -27.5% | +4.4% | +31.9 pp |
| 3-year CAGR | +79.2% | -0.7% | -79.9 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (212.39M) USD
- Year-over-year change
- +27.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (212.39M) | +27.5% |
| FY2024 | 2024-12-31 | (292.96M) | -174.3% |
| FY2023 | 2023-12-31 | (106.81M) | -189.5% |
| FY2022 | 2022-12-31 | (36.9M) | -49.3% |
| FY2021 | 2021-12-31 | (24.71M) | — |
Net Income vs competitors
How IMNM compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +26.9% is the 6th highest of 11, against a peer median of +27.4%.
- Over three fiscal years its annual growth of +79.2% compares with a peer median of +17.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $309.06M USD | +37.6% | +32.1% | 275948.2% | |
| LTM Sep 2026 | $282.65M USD | +26.9% | +79.2% | — | |
| LTM Mar 2026 | $218.8M USD | +7.2% | +24.8% | 344.6% | |
| LTM Mar 2026 | €217.14M EUR | +906.0% | — | 582.2% | |
| LTM Mar 2026 | $153.6M USD | -37.4% | +17.0% | 154.2% | |
| LTM Mar 2026 | $145.24M USD | +14.0% | +65.2% | — | |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $44.17M USD | +6.7% | -28.2% | — | |
| LTM Sep 2026 | $35.76M USD | +37.8% | -13.4% | — | |
| LTM Mar 2026 | $34.98M USD | +67.3% | +52.9% | — | |
| LTM Mar 2026 | $27.59M USD | +28.8% | -20.5% | 7.2% | |
| Peer median (excluding IMNM) | — | +27.4% | +17.0% | 249.4% | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| Deferred Income Tax | (500K) | (7.27M) | 0 | 0 | 0 |
| Stock-Based Compensation | 3.45M | 5.33M | 6.22M | 15.75M | 25.69M |
| Change in Working Capital | 2.78M | 2.24M | 12M | 14.87M | (15.23M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.78M | (677K) | (608K) | 9.53M | (9.16M) |
| Other Working Capital | 998K | 2.92M | 12.61M | 5.35M | (6.06M) |
| Other Non-Cash Items | 4K | 7.27M | 80.29M | 149.45M | 8.06M |
| Operating Cash Flow | (18.23M) | (28.69M) | (7.57M) | (110.79M) | (190.92M) |
| Capital Expenditures | (79K) | (248K) | (831K) | (53.51M) | (9.69M) |
| Acquisitions (Net) | 0 | 0 | 9.28M | 0 | 0 |
| Purchases of Investments | 0 | 0 | (38.93M) | (186.56M) | (123.27M) |
| Sales of Investments | 0 | 0 | 0 | 155M | 200M |
| Other Investing Activities | 0 | 0 | 0 | (46.34M) | (6.25M) |
| Investing Cash Flow | (79K) | (248K) | (30.48M) | (85.06M) | 60.8M |
| Debt Repayment | (113K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 27.23M | 32K | 34K | 250M | 640.36M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 656K | 0 | 116.37M | (9.47M) | 0 |
| Financing Cash Flow | 27.77M | 32K | 116.41M | 240.53M | 640.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 9.46M | (28.91M) | 78.36M | 44.67M | 510.24M |
| Free Cash Flow | (18.31M) | (28.94M) | (8.4M) | (164.3M) | (200.6M) |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$16.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.